nature neurOSCIenCe a r t I C l e S NS, an autosomal dominant genetic disorder with an incidence of ~1 in 2,500 live births, is characterized by facial abnormalities, short stature, motor delay and cardiac defects 1,2 . Importantly, 30-50% of patients with NS show cognitive deficits [3] [4] [5] [6] . Patients with NS also show clumsiness, motor delay, hearing loss, deficits in spatial knowledge and planning, and social and emotional problems 3, 4, 7 . Patients with NS also show impairments in hippocampal-dependent memory tasks 4, 8, 9 .
a r t I C l e S (repeated measures analysis of variance (ANOVA), F 1,18 = 2.078, P = 0.167) and had comparable swimming speeds in probe trials (WT, 17.33 ± 1.55 cm/s (mean ± s.e.m.), n = 11 mice; Ptpn11 N308D/+ , 18.37 ± 0.82 cm/s, n = 9 mice; unpaired two-tailed t-test, t = 0.554, P = 0.586). However, in probe trials Ptpn11 N308D/+ mutants spent significantly less time than did WT mice in the target quadrant (where the platform was located) during training ( Fig. 1b) (percentage of total time in the pool: WT, 57.87 ± 4.83%; Ptpn11 N308D/+ , 41.85 ± 4.30%; unpaired two-tailed t-test, t = 2.421, P = 0.0263). WT mice searched closer to the target during the probe trials than did mutants (WT, 32.53 ± 2.26 cm; Ptpn11 N308D/+ , 40.18 ± 2.05 cm; unpaired two-tailed t-test, t = 2.450, P = 0.0247). In contrast, Ptpn11 N308D/+ mutants performed normally in the visible-platform version of the water maze ( Supplementary Fig. 1 ), suggesting that the Ptpn11 N308D/+ mutation does not impair visuomotor function or motivation. After extended training, the Ptpn11 N308D/+ mutants reached a level of performance comparable to that of WT mice in probe trials, demonstrating that they can acquire spatial information, albeit at a slower rate than WT mice (Supplementary Fig. 2 ). In addition, Ptpn11 N308D/+ mutants showed deficits in contextual fear conditioning, another hippocampusdependent task (Supplementary Fig. 3 ).
In agreement with the greater severity of deficits associated with the D61G mutant as compared with the N308D mutant in both mice and humans 6, 15, 16, 18 , Ptpn11 D61G/+ mice showed more severe behavioral deficits than Ptpn11 N308D/+ mice. In probe trials, Ptpn11 D61G/+ mice did not search selectively in the target quadrant ( Fig. 1d ) (F 3,36 = 2.029, P = 0.127 and F 3,56 = 23.51, P < 0.0001 for Ptpn11 D61G/+ and WT, respectively; one-way ANOVA) and spent more time searching farther from the platform's former location than did WT littermates (WT, 46.23 ± 1.29 cm, n = 15 mice; Ptpn11 D61G/+ , 52.43 ± 2.14 cm, n = 10 mice; unpaired two-tailed t-test, t = 2.634, P = 0.0148). Even with additional training, Ptpn11 D61G/+ mice were unable to reach WT performance levels ( Supplementary  Fig. 2 ). Furthermore, Ptpn11 D61G/+ mice took longer to reach the platform during training for both hidden- (Fig. 1c) (repeated measures ANOVA, F 1,23 = 38.54, P < 0.0001) and visible-platform versions ( Supplementary Fig. 1 ) of the Morris water maze, and they showed slower swimming speeds (Ptpn11 D61G/+ , 11.98 ± 1.27 cm/s, n = 10; WT, 19.72 ± 0.46 cm/s, n = 15; unpaired two-tailed t-test, t = 6.618, P < 0.0001), which might have contributed to their longer latencies to reach the platform. Additional behavioral characterization in an open field test revealed that Ptpn11 D61G/+ mice were hypoactive (Supplementary Fig. 1 ). These data demonstrate that the behavioral deficits of Ptpn11 D61G/+ mice are not limited to spatial learning and memory abnormalities. Importantly, patients with NS also show neurological abnormalities other than cognitive deficits, such as higher rates of motor delay, clumsiness and poor coordination 2 .
NS mice show deficits in synaptic plasticity
Hippocampal LTP in the Schaffer collateral synapses of CA1 cells has a key function in spatial learning and memory 19 . To identify the mechanism responsible for the learning and memory deficits caused by the Ptpn11 mutations, we examined CA1 Schaffer collateral LTP in Ptpn11 N308D/+ and Ptpn11 D61G/+ mice by performing extracellular field Figure 2 NS mice show LTP deficits. (a) LTP induced by TBS (five bursts) in hippocampal slices from Ptpn11 N308D/+ mice and WT littermates (WT, n = 6 slices from 6 mice; Ptpn11 N308D/+ , n = 6 slices from 6 mice; repeated-measures ANOVA: F 1,10 = 7.893, P = 0.0185). (b) LTP induced by TBS (five bursts) in hippocampal slices from Ptpn11 D61G/+ and WT mice (WT, n = 7 slices from 7 mice; Ptpn11 D61G/+ , n = 7 slices from 6 mice; repeated-measures ANOVA: F 1,12 = 5.828, P = 0.0327). Field excitatory postsynaptic potential (fEPSP) slopes normalized to the average baseline response before LTP induction (time 0), plotted in 2-min blocks. Sample traces show responses during baseline (gray) and the last 10 min (black) of the recording (average of 10 recording traces). Vertical bar, 0.5 mV; horizontal bar, 4 ms. Control, no TBS. Error bars represent mean ± s.e.m. npg a r t I C l e S recordings in acute hippocampal slices. Samples from Ptpn11 N308D/+ and WT mice showed no substantial differences in basal synaptic transmission or paired-pulse facilitation (PPF) (Supplementary Fig. 4) . However, LTP induced with theta-burst stimulation (TBS; two or five theta bursts) was significantly reduced in Ptpn11 N308D/+ mice ( Fig. 2a and Supplementary Fig. 5 ) (last 10 min of recording, WT, 159.5 ± 4.23%, n = 6 slices from 6 mice; Ptpn11 N308D/+ , 143.4 ± 4.81%, n = 6 slices from 6 mice; unpaired two-tailed t-test, t = 2.506, P = 0.0311). Consistent with the hypothesis that these LTP deficits account for the learning impairments in Ptpn11 mutant mice, Ptpn11 D61G/+ mice, which have more severe learning impairments, also showed more severe LTP deficits than did Ptpn11 N308D/+ mice ( Fig. 2b) (last 10 min of recording, WT, 139.2 ± 8.41%, n = 7 slices from 7 mice; Ptpn11 D61G/+ , 110.8 ± 6.30%, n = 7 slices from 6 mice; unpaired two-tailed t-test, t = 2.698, P = 0.0194). As in Ptpn11 N308D/+ mice, basal synaptic transmission and PPF were normal in Ptpn11 D61G/+ mutants ( Supplementary Fig. 4 ).
PTPN11 D61G impairs LTP and memory in adult mice
The mutations in Ptpn11 knock-in mice are present throughout development, affect the entire body and could disrupt the function of brain structures other than the hippocampus. Similarly, NS is a systemic developmental disorder, and developmental defects are assumed to be responsible for the cognitive deficits in these patients 20 . Viral vectors provide spatial and temporal regulation of gene expression crucial for testing the specific role of Ptpn11 mutations in the adult mouse brain. Moreover, NS-associated alleles severely compromise the viability of mutant mice 14 , making it very difficult to obtain a sufficient number of mutant mice for all the studies we envisioned (Supplementary Table 1 ). To test whether altered Shp2 signaling in the adult hippocampus can cause LTP and, consequently, learning deficits, we overexpressed human PTPN11 D61G using recombinant adeno-associated virus (AAV-PTPN11 D61G ) in CA1, CA2 and CA3 of the hippocampus of adult WT mice. PTPN11 D61G overexpression in the hippocampus ( Fig. 3a and Supplementary Fig. 6 ) resulted in increased Erk activation as assessed by immunoblotting for phosphorylated Erk (p-Erk), confirming that AAV-PTPN11 D61G was functional (Fig. 3b) (n = 5 hippocampal slices for each group, unpaired two-tailed t-test, t = 2.452, P = 0.0398). AAV-PTPN11 D61G expression impaired performance in probe trials of the water maze (Fig. 3c) . Mice expressing AAV-PTPN11 D61G spent significantly less time in the target quadrant than did control mice expressing AAV-GFP (Fig. 3c ) (PTPN11 D61G , 25.89 ± 3.38%, n = 10; GFP, 35.88 ± 2.95%, n = 13; unpaired two-tailed t-test, t = 2.231, P = 0.0367). Unlike the Ptpn11 D61G/+ mutation and AAV-GFP (GFP/veh) mice (AAV-GFP, 154.8 ± 4.18%, n = 7; AAV-PTPN11 D61G , 131.9 ± 4.38, n = 10; unpaired two-tailed t-test, t = 3.625, **P = 0.0025) and significant reversal by SL327 treatment (146.1 ± 4.36%, n = 10; unpaired two-tailed t-test, t = 2.309, *P = 0.0330). SL327 did not affect LTP in the AAV-GFP group (146.2 ± 4.37%, n = 7; unpaired two-tailed t-test, t = 1.414, P = 0.183). n.s., not significant. npg a r t I C l e S in mice, AAV-PTPN11 D61G expression did not affect swimming speed or other performance variables during the acquisition phase of the water maze ( Supplementary Fig. 7 ), suggesting that the acute expression of PTPN11 D61G in the hippocampus affects only learning and memory, whereas deregulation of Shp2-Erk signaling during development in Ptpn11 D61G/+ mice might affect other functions, including motor coordination. Notably, overexpression of AAV-WT PTPN11 did not affect basal p-Erk levels or spatial learning and memory ( Supplementary Fig. 8 ), indicating that the adverse impact on Erk signaling and learning and memory is specific to the NS-related PTPN11 mutation. AAV-PTPN11 D61G -expressing mice were also tested in object-place recognition, another hippocampus-dependent task; mice expressing AAV-WT PTPN11 were used as controls (Fig. 3d) . In this task, mice are allowed to explore two identical objects located in opposite corners of the arena during training. One of the objects is moved to a new spatial location in the test session 24 h after training. Consistent with the water maze results, PTPN11 D61G expression in the CA fields of the hippocampus caused memory deficits in this task: control mice spent significantly more time exploring the object at the new location (Fig. 3d) (n = 15 mice, 59.79 ± 3.72% for new place, one-sample paired t-test compared to 50%, t = 2.633, P = 0.0197), but the PTPN11 D61G mice did not (Fig. 3d) (n = 15 mice, 52.61 ± 4.10% for new place, one-sample paired t-test compared to 50%, t = 0.636, P = 0.535). Importantly, AAV-PTPN11 D61G -expressing mice showed comparable total exploration time to that of control mice during training (control, 43.70 ± 3.98 s, n = 15; AAV-PTPN11 D61G , 39.29 ± 4.94 s, n = 15; unpaired t-test, t = 0.695 P = 0.493). Together, these data show that expressing PTPN11 D61G in the CA fields of the hippocampus in adult mice is sufficient to disrupt memory, and demonstrate that PTPN11 has a crucial role in adult brain function, in addition to its effects on development 20 .
To test whether reducing Erk activity could reverse the memory deficits in AAV-PTPN11 D61G -expressing mice, we treated these mice with the MEK inhibitor SL327 or vehicle daily, 30 min before training. SL327 treatment (32 mg per kilogram of body weight, intraperitoneal injection) decreased Erk activation in the hippocampus of control and AAV-PTPN11 D61G mice (Supplementary Fig. 9 ). This subthreshold dose of the drug does not impair spatial learning in WT mice and decreases hippocampal Erk activation in WT mice by only ~25% (Supplementary Fig. 9 ). Importantly, SL327 treatment rescued the spatial learning deficits in mice expressing AAV-PTPN11 D61G npg a r t I C l e S without affecting the performance of the AAV-GFP group ( Fig. 3c ; PTPN11 D61G treated with SL327, one-way ANOVA, F 3,36 = 10.44, P = 0.0001; target versus other quadrants, Dunnett's multiple comparison test, P < 0.05). Consistent with the water maze results, the same SL327 treatment also rescued the memory deficits in the object-place recognition task (Fig. 3e) (AAV-WT PTPN11, n = 5; 58.83 ± 2.01% for new place, two-tailed paired t-test compared to 50%, t = 4.395, P = 0.0117; AAV-PTPN11 D61G , n = 8; 59.90 ± 3.41% for new place, two-tailed paired t-test compared to 50%, t = 2.904, P = 0.0229). These results demonstrate that increased Ras-Erk signaling in CA fields of adult hippocampus contribute to the memory deficits in mice expressing AAV-PTPN11 D61G . Notably, SL327 also reversed the memory deficits of the adult Ptpn11 D61G/+ mice in the Morris water maze, showing that normalizing Erk activity in adults can reverse the behavioral deficits even in mutant mice with germline mutations (Supplementary Fig. 10 ). Next, we asked whether AAV-PTPN11 D61G expression in adults also impairs CA1 Schaffer collateral LTP. As in Ptpn11 D61G/+ mutant mice, hippocampal slices from AAV-PTPN11 D61G -expressing mice showed significantly reduced LTP in response to a TBS tetanus (Fig. 3f,g ) (GFP, 154.8 ± 4.18%, n = 7 slices from 7 mice; PTPN11 D61G , 131.9 ± 4.38%, n = 10 slices from 10 mice; unpaired two-tailed t-test, t = 3.625, P = 0.0025), demonstrating that manipulating Shp2 signaling specifically in the CA fields of the adult hippocampus is sufficient to impair LTP. In addition, TBS did not further activate Erk in AAV-PTPN11 D61G -expressing hippocampi (Fig. 3b) (n = 5 hippocampi from 5 mice for each group, unpaired two-tailed t-test, t = 1.580, P = 0.1527). SL327 treatment, which reversed their learning deficits, also normalized LTP in CA1 hippocampal slices from the AAV-PTPN11 D61G -expressing mice (Fig. 3f,g ) (two-way ANOVA, F 1,30 = 6.526, P = 0.0159; Bonferroni post-test revealed significant effect of SL327 treatment only on the PTPN11 D61G group, P < 0.05). It is noteworthy that basal synaptic transmission and paired-pulse facilitation were not affected by AAV-PTPN11 D61G expression or SL327 treatment ( Supplementary  Fig. 7 ). Taken together, these results indicate that deregulated Erk activity causes CA1 LTP deficits, and these deficits are responsible for the learning and memory impairments in mouse models of NS.
GFP PTPN11

PTPN11 D61G increases excitatory synaptic function
Next, we examined the electrophysiological mechanism underlying the LTP impairment in AAV-PTPN11 D61G -expressing mice. Increases in Ras signaling facilitate AMPA receptor trafficking to the surface membrane 21 . For example, expression of constitutively active Ras enhances AMPA receptor-mediated currents in hippocampal neurons and impairs LTP 21 . Hence, we asked whether the increases in activated Erk associated with PTPN11 D61G expression enhanced AMPA currents. Whole-cell voltage clamp recordings revealed that the AMPA/NMDA current ratio was increased in AAV-PTPN11 D61G -expressing hippocampi (Fig. 4a,b) (AAV-PTPN11 D61G , 1.51 ± 0.11, n = 10 cells from 5 mice; AAV-GFP, 0.96 ± 0.05, n = 10 cells from 5 mice, unpaired two-tailed t-test, t = 4.754, P = 0.0002). Importantly, SL327 treatment normalized the AMPA/NMDA ratio (Fig. 4a,b) (AAV-PTPN11 D61G , 1.07 ± 0.11, n = 7 cells from 6 mice; AAV-PTPN11 D61G treated with vehicle versus AAV-PTPN11 D61G treated with SL327, unpaired two-tailed t-test, t = 2.832, P = 0.0126). Although the PPF ratio was unaffected by AAV-PTPN11 D61G (Fig. 4c) (AAV-PTPN11 D61G , n = 12 cells from 5 mice; AAV-GFP, n = 11 cells from 5 mice; repeated-measures ANOVA, F 1,21 = 0.010, P = 0.921), miniature excitatory postsynaptic currents (mEPSC) frequency (but not amplitude) was enhanced by this manipulation (Fig. 4d) (AAV-GFP, 1.50 ± 0.53 Hz, n = 9 cells from 3 mice; AAV-PTPN11 D61G , 4.64 ± 0.94 Hz, n = 9 cells from 3 mice; unpaired two-tailed t-test, t = 2.923, P = 0.0100). The increased excitation in PTPN11 D61G -expressing mice was reversed by SL327 treatment ( Fig. 4d; vehicle, 4.64 ± 0.94 Hz, n = 9 cells from 3 mice; SL327, 2.02 ± 0.32 Hz, n = 9 cells from 5 mice; unpaired two-tailed t-test, t = 2.645, P = 0.0177). Consistently, mEPSC frequency, but not amplitude, was significantly higher in pyramidal neurons of Ptpn11 D61G/+ mice than in those of WT mice (Fig. 4e) (WT, 2.68 ± 0.55 Hz, n = 9 cells from 5 mice; Ptpn11 D61G/+ , 5.71 ± 0.56 Hz, n = 10 cells from 3 mice; unpaired two-tailed t-test, t = 3.858, P = 0.0013). Moreover, miniature inhibitory postsynaptic current (mIPSC) frequency and amplitude were unaffected in both AAV-PTPN11 D61G -transfected mice and Ptpn11 D61G/+ mutants (mIPSC frequency: AAV-GFP, 6.91 ± 0.87 Hz, n = 9 cells from 4 mice; AAV-PTPN11 D61G , 6.93 ± 1.15 Hz, n = 7 cells from 4 mice, unpaired two-tailed t-test, t = 0.022, P = 0.983; mIPSC amplitude: GFP, 19.13 ± 1.19 pA, n = 9 cells from 4 mice; AAV-PTPN11 D61G , 20.09 ± 1.62 pA, n = 7 cells from 4 mice, unpaired two-tailed t-test, t = 0.486, P = 0.634; mIPSC frequency: WT, 15.06 ± 2.08, n = 7 cells from 5 mice; Ptpn11 D61G/+ , 15.35 ± 3.50, n = 8 cells from 5 mice, unpaired two-tailed t-test, t = 0.0683, P = 0.947; mIPSC amplitude: WT, 32.91 ± 3.06 pA, n = 7 cells from 5 mice; Ptpn11 D61G/+ , 33.59 ± 2.32 pA, n = 8 cells from 5 mice, unpaired two-tailed t-test, t = 0.180, P = 0.860) (Fig. 4f,g ). Importantly, as with mice expressing AAV-PTPN11 D61G , the increased excitation in Ptpn11 D61G/+ mice was reversed by SL327 treatment (Fig. 4e) (vehicle, 5.71 ± 0.56 Hz, n = 10 cells from 3 mice; SL327, 2.87 ± 1.02 Hz, n = 9 cells from 3 mice; unpaired two-tailed t-test, t = 2.508, P = 0.0226), indicating that increased Ras-Erk signaling is responsible for the enhanced excitatory synaptic function associated with the Ptpn11 D61G mutation.
To test the hypothesis that the increase in excitation caused by the PTPN11 D61G mutation is due to increases in the number of synapses with AMPA receptors, we transfected cultured hippocampal neurons (21 d in vitro (DIV)) with PTPN11 D61G and labeled surface GluA1 Cadherin and Rab-4 were used as markers for surface and cytosol expression, respectively. (Full-length blots and gels are presented in Supplementary Fig. 11 .) (d) Surface and total expression of GluA1 in neurons expressing PTPN11 D61G or WT PTPN11. Error bars, mean ± s.e.m. Two-way ANOVA followed by Bonferroni post-test: F 1,12 = 5.704, P < 0.05; surface, WT PTPN11 versus PTPN11 D61G , *P < 0.05. npg a r t I C l e S AMPA receptors (Fig. 5a,b) . We found that the number of surface GluA1 receptor clusters was significantly higher in PTPN11 D61G -expressing neurons than in GFP-expressing controls (Fig. 5a,b ) (GluA1 particle number per 10 µm: PTPN11 D61G , 8.60 ± 0.59, n = 20 neurons, 1,432.6 µm of dendrites; GFP, 6.76 ± 0.34, n = 22 neurons, 1,759.6 µm of dendrites; unpaired two-tailed t-test, t = 2.763, P = 0.0086). This result is consistent with the increase in mEPSC frequency caused by PTPN11 D61G . The size of GluA1 clusters, however, was not affected by PTPN11 D61G expression (Fig. 5a,b ) (GluA1 particle size (µm 2 ): PTPN11 D61G , 0.19 ± 0.02, n = 20 neurons, 1,432.6 µm of dendrites; GFP, 0.18 ± 0.02, n = 22 neurons, 1,759.6 µm of dendrites; unpaired two-tailed t-test, t = 0.319, P = 0.751), a result consistent with the finding of normal mEPSC amplitude. To quantitatively analyze the surface expression of GluA1, cultured neurons transfected with WT PTPN11 or PTPN11 D61G were surface labeled with biotin, and the biotinylated surface proteins were pulled down and analyzed (Fig. 5c,d) . Whereas the total expression levels of GluA1 were similar in neurons expressing WT PTPN11 and PTPN11 D61G , the surface expression of GluA1 was significantly higher in PTPN11 D61G -expressing neurons than in WT PTPN11-expressing neurons (Fig. 5c,d ) (two-way ANOVA followed by Bonferroni post-test: interaction between fraction (total/surface) × virus (PTPN11/PTPN11 D61G ), F 1,12 = 5.704, P = 0.0342; total, PTPN11 versus PTPN11 D61G , P > 0.05; surface, PTPN11 versus PTPN11 D61G , P < 0.05). These data support the results from the immunocytochemistry experiments showing that PTPN11 D61G expression facilitates the surface expression of GluA1. These results indicate that postsynaptic changes in AMPA receptor trafficking contribute to the increase in excitatory synaptic function caused by the PTPN11 D61G mutation.
Lovastatin rescues deficits in Ptpn11 D61G/+ mice SL327 rescued the spatial learning deficits in adult Ptpn11 D61G/+ mice ( Supplementary Fig. 10 ), suggesting that decreasing basal Erk activation can be a therapeutic strategy for learning deficits in NS. Lovastatin, a member of the statin class of drugs, which permeate the blood-brain barrier and are approved by the US Food and Drug Administration (FDA), inhibits Ras isoprenylation required for the membrane localization and biological activity of Ras 22, 23 . As in AAV-PTPN11 D61G -transfected mice, p-Erk levels were increased in Ptpn11 D61G/+ hippocampi ( Fig. 6a) (WT, 100.0 ± 7.23%, n = 8; Ptpn11 D61G/+ , 128.2 ± 2.87%, n = 7; unpaired two-tailed t-test, t = 3.438, P = 0.0044). Lovastatin treatment normalized p-Erk levels in hippocampus from Ptpn11 D61G/+ mice at concentrations that did not affect Erk activation in controls (Fig. 6a) Supplementary  Fig. 11 .) Right, bar graph displaying normalized p-Erk levels (mean ± s.e.m.). WT, n = 8 hippocampi, Ptpn11 D61G/+ , n = 7 hippocampi, unpaired two-tailed t-test, t = 3.438, *P = 0.0044. Ptpn11 D61G/+ treated with vehicle, n = 7 hippocampi, Ptpn11 D61G/+ with lovastatin, n = 8 hippocampi, unpaired two-tailed t-test, t = 2.231, *P = 0.0439. , n = 7 slices from 5 mice; WT-lovastatin, 150.7 ± 5.49%, n = 6 slices from 4 mice; Ptpn11 D61G/+ -vehicle, 131.7 ± 2.31%, n = 9 slices from 5 mice; Ptpn11 D61G/+ -lovastatin, 154.2 ± 6.88%, n = 7 slices from 6 mice; unpaired two-tailed t-test, **P = 0.0031, ***P < 0.001). Error bars, mean ± s.e.m.; veh, vehicle; lova, lovastatin; n.s., not significant. npg a r t I C l e S n = 7; lovastatin, 111.8 ± 6.41%, n = 8; unpaired two-tailed t-test, t = 2.231, P = 0.0439). Importantly, Ptpn11 D61G/+ mice treated with lovastatin performed better (for example, reaching the hidden platform of the Morris maze faster) than those treated with vehicle only (Fig. 6b) (latency to the platform, two-way ANOVA followed by Bonferroni post-test, WT treated with vehicle versus Ptpn11 D61G/+ treated with vehicle, day 3 P < 0.01, day 4-7 P < 0.001; Ptpn11 D61G/+ treated with vehicle versus Ptpn11 D61G/+ treated with lovastatin, day 5 P < 0.05), although their swimming speeds were unchanged by the treatment (Fig. 6c ) (WT treated with vehicle, 18.5 ± 0.6 cm/s, n = 14 mice; Ptpn11 D61G/+ treated with vehicle, 13.6 ± 1.3 cm/s n = 11 mice; WT treated with lovastatin, 17.9 ± 0.8 cm/s, n = 13 mice; Ptpn11 D61G/+ treated with lovastatin, 14.2 ± 1.1 cm/s, n = 11 mice; two-way ANOVA with genotype as between-subjects factor and drug treatment as within-subjects factor, effect of genotype: F 1,45 = 19.79, P < 0.0001, interaction: F 1,45 = 0.4489, P = 0.506). These data suggest that the learning deficits observed in these mice are not an artifact of their slower swimming speeds or other performance deficits. In probe trials, lovastatin-treated Ptpn11 D61G/+ mice, unlike vehicle-treated Ptpn11 D61G/+ mice, showed selective searching in the target quadrant (Fig. 6d,e) . During probe trials, lovastatin-treated Ptpn11 D61G/+ mice showed lower average proximity to the platform site (i.e., better performance) than vehicle-treated Ptpn11 D61G/+ mice, indicating that lovastatin treatment improved the performance of Ptpn11 D61G/+ mice in probe trials (Fig. 6d,e) (Fig. 6d,e) . At the concentration used, lovastatin had no effect on any measure of learning in WT mice (Fig. 6d,e) . Consistent with the hypothesis that increased Ras-Erk activity leads to the LTP deficits responsible for spatial learning impairment in Ptpn11 mutant mice, the levels of LTP induced by 5 TBS were significantly higher in Ptpn11 D61G/+ mice treated with lovastatin than in those treated with vehicle and were indistinguishable from those in WT controls (Fig. 6f,g ) (two-way ANOVA with genotype as between-subjects factor, F 1,25 = 5.936, P = 0.0223, Bonferroni posttest revealed a significant effect of lovastatin treatment only on Ptpn11 D61G/+ group, P < 0.01). By contrast, lovastatin treatment had no effect on LTP in hippocampal slices from WT mice (Fig. 6f,g ). Thus, lovastatin treatment can normalize LTP deficits and spatial learning impairments even in adult Ptpn11 D61G/+ mice. Although we cannot exclude the possibility that lovastatin may affect other biological processes 24 , our data suggest that lovastatin reverses spatial learning deficits in Ptpn11 D61G/+ mice by reducing Erk activation and, consequently, correcting LTP deficits.
DISCUSSION
Our study provides compelling evidence that the spatial learning and memory deficits in mouse models of NS are caused by enhanced RasErk activation, which disrupts the balance between excitation and inhibition and impairs hippocampal LTP. Furthermore, our experiments with viral vectors demonstrate that Ptpn11 has critical roles not only in regulating development 20, 25 , but also in adult brain functions. Consistent with our findings, expression of the fly ortholog of SHP2 (Csw) bearing gain-of-function mutations impaired long-term memory in Drosophila 26 .
In the present study, we used two knock-in mutant mice harboring a Ptpn11 D61G or a Ptpn11 N308D mutation. The D61G mutation is associated with both NS and leukemia and shows higher enzymatic activity than N308D, which is associated only with NS 15 . Consistently, Ptpn11 D61G/+ mice showed more severe deficits in LTP and learning than Ptpn11 N308D/+ mice. Although basal level of p-Erk was significantly higher in the hippocampus of Ptpn11 D61G/+ mice than in WT littermates (Fig. 6) , we could not detect significant increases in basal p-Erk in the hippocampus of Ptpn11 N308D/+ mice, perhaps because these mice had deficits that were milder overall (Supplementary Fig. 9c) .
The activation of Ras-Erk signaling facilitates AMPA receptor trafficking during LTP 21 , and abnormal hyperactivation of postsynaptic Erk signaling impairs hippocampal LTP and learning 27, 28 . Our findings suggest that the PTPN11 D61G mutation increases the number of synapses with postsynaptic AMPA receptors, thus occluding LTP and therefore impairing learning. In agreement with the hypothesis that there are more synapses with AMPA receptors in PTPN11 D61G -expressing neurons than in GFP-expressing neurons, we found that PTPN11 D61G expression increases mEPSC frequency but does not affect the PPF ratio (Fig. 4c) , a form of plasticity very sensitive to changes in presynaptic function. Additionally, PTPN11 D61G expression increased the evoked AMPA/NMDA ratios (Fig. 4a,b) , another observation consistent with the hypothesis that the PTPN11 D61G expression results in more synapses with AMPA receptors. Importantly, these observations were reproduced in both AAV-PTPN11 D61G -transfected mice and in the germline mutants. Importantly, PTPN11 D61G expression enhanced the surface expression of GluA1 and increased the number of surface GluA1 clusters in cultured hippocampal neurons, a finding consistent with the hypothesis that the enhancement in excitatory synaptic function driven by PTPN11 D61G expression is caused by postsynaptic mechanisms. Interestingly, deletion of a Ras-Erk regulator (SynGAP) has been reported to increase Erk signaling, increase mEPSC frequency and impair LTP 27 .
Deregulation of Ras-Erk signaling has been associated with other genetic disorders, including neurofibromatosis type I (NF1), Costello syndrome, LEOPARD syndrome, cardiofaciocutaneous syndrome and Legius syndrome 10, 29 . Among these, studies with Nf1 +/− mice, a model of NF1, demonstrated that increased Ras signaling results in increased GABA release (excitation is normal in these mice) that leads to deficits in LTP and, consequently, learning and memory impairments [30] [31] [32] [33] .
Together, these findings demonstrate that similar behavioral phenotypes (for example, spatial learning deficits) and even electrophysiological phenotypes (i.e., LTP deficits) can be caused by different cellular mechanisms: increases in AMPA receptors in NS mice and increases in GABA release in NF1 mice. Homozygous deletion of Nf1 in mouse postnatal excitatory neurons does not affect synaptic transmission or learning 32 , whereas expression of PTPN11 D61G in postnatal excitatory neurons disrupts both synaptic transmission and learning, a direct demonstration of the distinct roles of these two Ras signaling modulators.
Here we show that postnatal treatment with lovastatin, an FDAapproved drug with a strong safety profile, can reverse deficits in learning and memory as well as in LTP in an adult NS mouse model. A previous study showed that lovastatin treatment can rescue spatial learning problems, attention deficits and pre-pulse inhibition deficits in Nf1 +/− mutant mice 22 . Thus, our studies suggest that lovastatin may also be useful for treatment of cognitive deficits associated with NS. 
